<DOC>
	<DOCNO>NCT01582269</DOCNO>
	<brief_summary>The purpose study see whether treatment LY2157299 , LY2157299 plus lomustine therapy lomustine plus placebo help participant brain cancer</brief_summary>
	<brief_title>A Study Recurrent Glioblastoma ( GB )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>Histological confirm diagnosis relapse intracranial GB Progressive Disease ( PD ) follow standard chemoradiation Prior surgical resection allow Performance status Eastern Cooperative Oncology Group ( ECOG ) 0 1 Adequate hematologic , hepatic renal function Discontinued prior cancer treatment cancer &amp; recover acute effect therapy Tumor specimen must available central pathology review prognostic predictive biomarker evaluation Moderate severe heart disease base New York Heart Association ( NYHA ) criteria Prior nitrosurea therapy ( include lomustine Gliadel ) Prior bevacizumab 1st line treatment GB ( treatment conclude 12 month prior enrollment , patient may eligible participate trial ) Current acute chronic myelogenous leukemia Second primary malignancy may affect interpretation result Serious concomitant systemic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>